Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP[3-30]NH2 in Fasting Metabolism and Obesity
NCT06368752Phase 1Enrolling by invitation
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GIP(3-30)NH2 in obesity. Primary endpoint: Plasma glucagon concentrations at 4 hours. Started May 2023; status: enrolling by invitation.
02
Drugs
GIP(3-30)NH2
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06368752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06368752.